RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:293168

Infantile-onset ascending hereditary spastic paralysis

low confidenceDisorder

Also known as: IAHSP

Query health: suspect — Only one of 2 strategies returned hits (phrase).

Publications

57,463

Trials

0

Interventional, condition-specific

Researchers

5,074

Distinct authors in sample

Gene link

ALS2

Strong

Readiness

3/6

Stages with a signal

Clinical definition (Orphanet)

-onset ascending spastic paralysis (IAHSP) is a very rare motor neuron disease characterized by severe spasticity of the lower limbs in early life, progression of spasticity to the upper limbs in late childhood, and dysarthria.

How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

3/6 stages with a signal

No matched interventional trial; the gene is known and literature exists — preclinical or natural-history work may still be the practical next step.

  1. Gene identifiedPresent

    Strong — ALS2

  2. LiteraturePresent

    57,463 matched papers (36,916 in last 10 years) Source

  3. Phenotype characterisedPresent

    32 HPO annotations (e.g. Abnormality of eye movement; Spastic paraplegia; Dysarthria) Source

  4. Animal modelNot found

    No Alliance genotype “model of” associations via Monarch for these Mondo IDs

  5. Orphan designationNot found

    No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source

  6. Interventional trialNot found

    No matched interventional trial under our ClinicalTrials.gov rules

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Yes — we know a specific gene responsible (ALS2).

GenCC classification: Strong.

Phenotypes (Monarch / HPO)

32

Associated phenotypes · MONDO:0011797

  • Abnormality of eye movement
  • Spastic paraplegia
  • Dysarthria
  • Hyperreflexia
  • Pseudobulbar affect

Showing 5 of 32 — open Monarch for the full list.

Animal models (Monarch / Alliance)

None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.

Monarch fetch 2026-07-29

Therapies

Designations, candidates, and chemicals

FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.

Orphan designation (FDA · EMA)

No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.

Open Targets candidates

No drugs or clinical candidates returned for this Mondo ID on Open Targets.

CTD chemicals (MyDisease.info)

No CTD chemical associations returned for this Mondo ID.

Literature

Is anyone studying this?

57,463

57,463 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.

57,463 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).

36,916 in the last 10 years · low confidence

Phrase hits: 135 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

5,074

Distinct author names in 135 sampled papers — named people below.

Who's working on it?

No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.

  1. 01
    Wang Y13 papers · 2021

    Saint Louis University, Department of Biology, Saint Louis, MO, USA.

    Papers in Europe PMC
  2. 02
    Zhang H11 papers · 2021

    Thomas Jefferson University/Vickie & Jack Farber Institute for Neuroscience, Hospital for Neuroscience, Philadelphia, PA, USA.

    Papers in Europe PMC
  3. 03
    Liu X10 papers · 2023

    University of Colorado at Boulder, Department of Biochemistry, Boulder, CO, USA.

    Papers in Europe PMC
  4. 04
    Zhang Y10 papers · 2021

    The Chinese University of Hong Kong, Department of Anaesthesia and Intensive Care, Hong Kong, China.

    Papers in Europe PMC
  5. 05
    Chen Y8 papers · 2021

    Research Institute in Oncology and Hematology, CancerCare Manitoba, Winnipeg, Manitoba, Canada.

    Papers in Europe PMC
  6. 06
    Hadano S8 papers · 2022

    Tokai University School of Medicine, Department of Molecular Life Sciences, Isehara, Kanagawa, Japan.

    Papers in Europe PMC
  7. 07
    Zhang L8 papers · 2021

    Huazhong University of Science and Technology, College of Life Science and Technology, Key Laboratory of Molecular Biophysics of Ministry of Education,Wuhan, Hubei, China.

    Papers in Europe PMC
  8. 08
    Li M7 papers · 2021

    Jinan University, College of Life Science and Technology, Department of Biology, Guangzhou, China.

    Papers in Europe PMC
  9. 09
    Liu Y7 papers · 2021

    Tsinghua Unversity, School of Life Sciences, Beijing, China.

    Papers in Europe PMC
  10. 10
    Wang C7 papers · 2021

    Huazhong University of Science and Technology, College of Life Science and Technology, Hubei Bioinformatics and Molecular Imaging Key Laboratory, Key Laboratory of Molecular Biophysics of Ministry of Education, Wuhan, Hubei, China.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

0

interventional trials for this specific condition

No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).

Data as of 11 September 2026 · last trial check 11 September 2026

No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.

low confidence · 38.6th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.

See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.

Other registries (secondary)

Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.

raw 0 · after dedupe 0 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 0 · dropped 0 · fetched 2026-07-30

Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri

No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).

Where to find support

Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.

Orphanet entry for Infantile-onset ascending hereditary spastic paralysis — check Associations / patient organisations on that page.

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

("Infantile-onset ascending hereditary spastic paralysis" OR "IAHSP") OR (MESH:"Hereditary spastic paralysis, infantile onset ascending") OR ("ALS2" OR "ALS2 syndrome" OR "ALS2-related")

Run this search on Europe PMC

MeSH descriptor terms unioned into the query: Hereditary spastic paralysis, infantile onset ascending

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Infantile-onset ascending hereditary spastic paralysis" OR "IAHSP" OR "Hereditary spastic paralysis, infantile onset ascending"

Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.

Query health: suspect — strategies attempted: phrase, mesh; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus
  • Publication count (57463) is implausibly high for prevalence class "<1 / 1 000 000" — treat as possible over-matching, not a measure of research intensity

Ingested 2026-07-27T12:19:26.734Z